Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 16/20 | 1.00 |
| ▸ | CCR2 | P41597 | 5/20 | 1.00 |
| ▸ | CXCR3 | P49682 | 3/20 | 1.00 |
| ▸ | CCR7 | P32248 | 2/20 | 1.00 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29381708 | 1.00 | CCR5 (1.00) | CCR5CCR2CXCR3CCR7CXCR5 | |
| SCHEMBL30241629 | 0.99 | CCR5 (1.00) | CCR5CCR2CXCR3CCR7CXCR5 | |
| SCHEMBL1161322 | 0.99 | CCR5 (1.00) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Iodide SCHEMBL3031616 | 0.98 | CCR5 (1.00) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Hydrochloric Acid SCHEMBL7623097 | 0.92 | CXCR3 (0.88) | CCR5CCR2CXCR3CCR7CXCR5 | |
| SCHEMBL12926185 | 0.92 | CCR5 (0.86) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Iodide SCHEMBL5204391 | 0.89 | CCR5 (1.00) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Iodide SCHEMBL7681118 | 0.88 | CCR5 (1.00) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Hydrochloric Acid SCHEMBL2900185 | 0.87 | CCR5 (0.78) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Hydrochloric Acid SCHEMBL2900998 | 0.87 | CXCR3 (0.80) | CCR5CCR2CXCR3CCR7CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1077 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130315981-A1 | METHOD FOR INDUCING FAT LOSS IN MAMMALS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-11-28 | — | — | US | claimed |
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | claimed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | claimed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | claimed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | claimed |
| US-20050154016-A1 | Preventives for hiv infection | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | claimed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| US-20030078189-A1 | Medicinal compositions for oral use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-04-24 | — | — | US | claimed |
| EP-1236476-A1 | MEDICINAL COMPOSITIONS FOR ORAL USE | Takeda Chemical Industries, Ltd. (JP) | 2002-09-04 | — | — | EP | claimed |
| US-6376536-B1 | VIRICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | claimed |
| US-6096780-A | ANTIVIRAL COMPOUND USEFUL FOR TREATING HIV VIRUSES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-01 | — | — | US | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137709-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| US-6096780-A | ANTIVIRAL COMPOUND USEFUL FOR TREATING HIV VIRUSES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| WO-2000010965-A2 | QUATERNARY AMMONIUM SALTS AND THEIR USE AS ANTI-HIV AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154016-A1 | Preventives for hiv infection | CCR5, CCR2, CCR1 | CCR5 1/4885CCR2 2/4885CXCR3 19/4885 |
| US-20030078189-A1 | Medicinal compositions for oral use | CCR5, CXCR3, CCL5 | CCR5 1/4885CCR2 23/4885CXCR3 2/4885 |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | NR2C2, NR3C2, OXER1 | CCR5 3504/4885CCR2 583/4885CXCR3 2613/4885 |
| US-20050245537-A1 | Use of compounds having ccr antagonism | CCR1, CCR3, CCR2 | CCR5 9/4885CCR2 3/4885CXCR3 11/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | CCR5 9/4885CCR2 3/4885CXCR3 11/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | CCR5 3552/4885CCR2 1476/4885CXCR3 3090/4885 |
| US-20260137709-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR3C1, NR3C2, NR4A1 | CCR5 114/4885CCR2 30/4885CXCR3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.